The European Commission (EC) has authorised the marketing of Bavarian Nordic's Vimkunya - the first chikungunya vaccine ...
The CHMP recommends conditional marketing authorization of REGN's linvoseltamab to treat adults with relapsed and refractory multiple myeloma.
LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatmen ...
The CHMP recommends granting a marketing authorization to NVS' Fabhalta for the treatment of adults with C3 glomerulopathy, an ultra-rare, progressive kidney disease with no currently approved ...
Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...
Approximately one to two people per million worldwide are diagnosed with the ultra-rare kidney disease every year ...
The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...
The CHMP gives a positive opinion to Eli Lilly's Jaypirca in patients with relapsed or refractory CLL in a post-BTK inhibitor setting.
February brought policy updates and several biosimilar approvals, including the first FDA approval for an insulin aspart ...
Hosted on MSN2d
CHMP recommends AbbVie’s Rinvoq be approved for adult GCAThe treatment has gained approval in the European Union (EU) for a range of conditions, including psoriatic arthritis, ...
About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.
Right now, Rinvoq is approved in the European Union and the U.S. for the treatment of adults with radiographic axial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback